FDA approves Deciphera’s Romvimza for rare tumour type
Tenosynovial giant cell tumours can cause pain, stiffness, swelling and movement limitations The US Food and Drug Administration (FDA) has...
Selected News
UK study highlights importance of GP data in understanding atrial fibrillation
The common heart condition affects approximately 1.5 million people in the UK A new UK study has highlighted the critical...
NHS England launches first-ever breast cancer screening campaign
New data has shown that around a third of women do not attend screenings after being invited NHS England has...
Cambridge scientists develop ‘super test’ for prostate cancer
New test aims to revolutionise prostate cancer screening Scientists in Cambridge have developed a new ‘super test’ for prostate cancer...
Bath researchers awarded Wellcome grant for psychotic disorder study
New funding to investigate cognitive decline and brain ageing The University of Bath has received a £3.5 million Wellcome grant...
Andembry treatment approved across Europe
Significant progress for hereditary angioedema condition Global biotechnology leader CSL has announced that the European Commission (EC) has approved ANDEMBRY...
Illuccix therapy gets approval in the UK
Imaging agent to improve prostate cancer detection Telix Pharmaceuticals has announced that the UK’s Medicines and Healthcare Products Regulatory Agency...
Amlenetug receives FDA Fast Track Designation
Potential treatment for multiple system atrophy shows promise Lundbeck’s investigational drug, amlenetug, has been granted Fast Track Designation by the...
Bimekizumab shows long-term efficacy in hidradenitis suppurativa
UCB's BIMZELX reveals promising two-year data at EHSF 2025 UCB has announced impressive two-year data for BIMZELX (bimekizumab) at the...
Libtayo available in Scotland for cervical cancer patients
New immunotherapy offers hope for recurrent cervical cancer Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has...
Lynparza approved in Scotland for BRCA-mutated breast cancer patients
Treatment expands options for HER2-negative metastatic breast cancer AstraZeneca announced that its drug Lynparza (olaparib) has been approved for use...
Capgemini unveils AI breakthrough to boost bioeconomy
New methodology may boost innovation in protein engineering Capgemini has introduced a pioneering generative AI-driven methodology for protein engineering, utilising...
Hemgenix shows efficacy among haemophilia B patients
CSL Behring's study reveals significant long-term benefits New data from CSL Behring’s HOPE-B study demonstrates that Hemgenix (etranacogene dezaparvovec-drlb) gene...
Qureight and Avalyn launch strategic partnership in pulmonary fibrosis
Partnership aims to leverage cutting-edge technology in clinical trials Qureight Ltd and Avalyn Pharma Inc have announced a strategic partnership...
FDA grants Orphan Drug Designation to Ariceum cancer therapy
Designation follows promising preclinical data and FDA clearance Ariceum Therapeutics, a private biotech company based in Berlin, has announced that...
Novartis secures MHRA authorisation for ribociclib
Breast cancer therapy offers hope for patients at risk of recurrence Novartis UK announced the Medicines and Healthcare products Regulatory...
Grifols collaborates with startup FcR Therapeutics to develop autoimmune therapies
Partnership aims to create recombinant nanobodies to treat immune disorders Grifols, a global healthcare company and leading manufacturer of plasma-derived...
Algiax announces results from phase 2a trial for neuropathic pain treatment
Study shows AP-325 offers lasting pain relief without central side effects Algiax Pharmaceuticals, a company committed to developing innovative treatments...
Aplagon secures EUR 7 million for APAC phase 2a trials
Funding led by new investors FSG and EIC Fund Helsinki-based Aplagon has raised EUR 7 million to advance its APAC...
CHMP recommends SC Rybrevant for EGFR-mutated NSCLC patients
Positive opinion issued for marketing authorisation extension The Committee for Medicinal Products for Human Use (CHMP) has recommended extending marketing...
